IMPLANET Announces Further Strategic Distribution Agreements and Recruitments in the United States

Regulatory News:

IMPLANET (Paris:IMPL) (Euronext: IMPL, FR0010458729), a medical technology company specializing in vertebral and knee-surgery implants, announces, within the framework of its plan to develop its sales and structure its teams in the United States, the signing of a distribution agreement with two new partners, as well as the appointment of a Sales Director and a Marketing and Training Director.

In accordance with the market plan presented at the time of its IPO, Implanet is extending its network of sales agents in the United States. These two new distributors will supplement the Company’s existing three partners and will enable it to strengthen its presence in the south and east of the country in order to market JAZZ in four more states: Ohio, Louisiana, Mississippi and Alabama. Thus far, Implanet had a presence on the west coast of the USA and in Florida.

Simultaneously, the Company announces the recruitment of two new members of staff, spine surgery experts with substantial experience amongst American majors, one as Sales Director for the Western United States and the other as Marketing and Training Director.

"We are delighted with the signing of these two additional partnerships that will enable us to extend our coverage of the United States and reaffirm our growth dynamic there. We are also very pleased to have recruited two spine specialists with considerable experience of the local market in order to structure and support our expansion. We are continually striving to select the best possible partners and staff with regard to our international development objectives”, says Ludovic Lastennet, CEO of Implanet.

About IMPLANET
Founded in 2007 and based near Bordeaux, IMPLANET is a medical technology company that manufactures high-quality implants for orthopedic surgery. Its flagship product, the JAZZ latest-generation implant, aims to improve the treatment of spinal pathologies requiring vertebral fusion surgery. IMPLANET’s proven orthopedic platform, based on perfectly controlling the traceability of its products, gives the Company the proven ability to enhance this innovation. Protected by four families of international patents, JAZZ has obtained 510(k) regulatory approval from the Food and Drug Administration (FDA) in the United States and the CE mark. IMPLANET employs 33 staff and recorded 2012 sales of €6.6 million.

For further information, please visit www.implanet.com